Randomized phase II trial of preoperative fulvestrant with or without enzalutamide for ER+/Her2- primary breast cancer
RNA-seq (gene expression) · human · 86 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Topic
- Breast cancerThis series is part of our curated briefing on it.
- Samples
- 86 samples: 86 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Clinical and immune responses to neoadjuvant fulvestrant with or without enzalutamide in ER+/Her2- breast cancerNPJ breast cancer · 2024
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE271080_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1129573 and SRA study SRP516871. Searching any of these in the dataset finder brings you back here.
Any grouping that defines a comparison lives in the sample characteristics, which GEO records separately from the titles.
How we read this: Read from 86 sample titles: 86 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8368290 Breast tumor 01_001 from Combination Arm sample type B
- GSM8368291 Breast tumor 01_002 from Fulvestrant Arm sample type W
- GSM8368292 Breast tumor 01_004 from Combination Arm sample type B
- GSM8368293 Breast tumor 01_004 from Combination Arm sample type W
- GSM8368294 Breast tumor 01_006 from Combination Arm sample type B
- GSM8368295 Breast tumor 01_006 from Combination Arm sample type W
- GSM8368296 Breast tumor 01_007 from Fulvestrant Arm sample type B
- GSM8368297 Breast tumor 01_007 from Fulvestrant Arm sample type W
- GSM8368298 Breast tumor 01_008 from Fulvestrant Arm sample type W
- GSM8368299 Breast tumor 01_009 from Combination Arm sample type B
- GSM8368300 Breast tumor 01_009 from Combination Arm sample type W
- GSM8368301 Breast tumor 01_011 from Combination Arm sample type B
- GSM8368302 Breast tumor 01_011 from Combination Arm sample type W
- GSM8368303 Breast tumor 01_012 from Combination Arm sample type B
- GSM8368304 Breast tumor 01_012 from Combination Arm sample type W
- GSM8368305 Breast tumor 01_013 from Combination Arm sample type B
- GSM8368306 Breast tumor 01_013 from Combination Arm sample type W
- GSM8368307 Breast tumor 01_014 from Fulvestrant Arm sample type B
- GSM8368308 Breast tumor 01_015 from Combination Arm sample type W
- GSM8368309 Breast tumor 01_016 from Fulvestrant Arm sample type B
- GSM8368310 Breast tumor 01_018 from Combination Arm sample type B
- GSM8368311 Breast tumor 01_020 from Combination Arm sample type B
- GSM8368312 Breast tumor 01_020 from Combination Arm sample type W
- GSM8368313 Breast tumor 01_021 from Combination Arm sample type B
- GSM8368314 Breast tumor 01_021 from Combination Arm sample type W
- GSM8368315 Breast tumor 01_023 from Combination Arm sample type B
- GSM8368316 Breast tumor 01_023 from Combination Arm sample type W
- GSM8368317 Breast tumor 02_001 from Fulvestrant Arm sample type B
- GSM8368318 Breast tumor 02_001 from Fulvestrant Arm sample type W
- GSM8368319 Breast tumor 02_002 from Combination Arm sample type B
- GSM8368320 Breast tumor 02_002 from Combination Arm sample type W
- GSM8368321 Breast tumor 02_003 from Combination Arm sample type B
- GSM8368322 Breast tumor 02_003 from Combination Arm sample type W
- GSM8368323 Breast tumor 02_004 from Combination Arm sample type B
- GSM8368324 Breast tumor 02_004 from Combination Arm sample type W
- GSM8368325 Breast tumor 02_005 from Fulvestrant Arm sample type B
- GSM8368326 Breast tumor 02_005 from Fulvestrant Arm sample type W
- GSM8368327 Breast tumor 02_007 from Fulvestrant Arm sample type B
- GSM8368328 Breast tumor 02_007 from Fulvestrant Arm sample type W
- GSM8368329 Breast tumor 02_008 from Fulvestrant Arm sample type B
+ 46 more — browse all 86 samples with per-sample file links →
- GSE104193 Hypoxia-mediated translational activation of ITGB3 in breast cancer cells enhances TGF-β signalling and malignant features in vitro and in vivo 32 samples same disease briefing · shares breast
- GSE104675 Role for the Transcriptional Activator ZRF1 in Breast Cancer Progression and Endocrine Resistance 6 samples same disease briefing · shares breast
- GSE10886 A Supervised Risk Predictor of Breast Cancer Based on Biological Subtypes 226 samples same disease briefing · shares breast
- GSE11121 The humoral immune system has a key prognostic impact in node-negative breast cancer 200 samples same disease briefing · shares breast
- GSE10885 An integromic analysis reveals that metaplastic carcinomas are distinct from basal-like tumors. 244 samples same disease briefing
- GSE297715 Epigenetic and 3D Genome Changes Drive Primary Trastuzumab Resistance in HER2+ Breast Cancer 20 samples shares her2, primary, breast
- GSE243375 HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial 287 samples shares her2, breast
- GSE234519 NSABP B-41: A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer 245 samples shares her2, breast
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.